NCT07395089Completed
Computed Tomography of Pulse-Field Ablation
Atrial Remodeling Associated With Pulse-Field Ablation of Atrial Fibrillation: a Computed Tomography Study
Source: ClinicalTrials.gov · Last updated 8 Sept 2026
Brief summary (registry, in English)
Radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF) reduces left atrial (LA) volume post-ablation, a phenomenon termed reverse atrial remodeling, indicative of successful reversal of atrial cardiomyopathy progression. In contrast, pulse field ablation (PFA), a novel non-thermal technology, offers a promising efficacy and safety profile without inducing persistent atrial fibrosis. While RFCA-associated reverse atrial remodeling is well-documented, it remains uncertain whether PFA, operating on a non-thermal paradigm, also promotes this remodeling, which would enhance its physiological relevance in AF treatment. Additionally, RFCA studies show that LA wall thickness at the pulmonary vein (PV) antrum can predict PV reconnection and arrhythmia recurrence, but whether PFA affects LA thinning or enables similar predictions from post-treatment computed tomography (CT) scans is unknown. Moreover, epicardial adipose tissue (EAT), strongly linked to LA abnormalities and AF recurrence, can be quantified via CT, yet the impact of PFA on LA EAT remains unexplored. Finally, PFA's versatility, particularly in isolating the LA posterior wall (LAPW) in non-paroxysmal AF, raises questions about its effect on posterior wall thinning or EAT changes, factors associated with post-ablation recurrence
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 90 (actual)
- First submitted
- 28 Nov 2025
- Start date
- 15 Apr 2026
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Atrial fibrillation
- NCT number
- NCT07395089
What you commit to
- Study type: Observational
- Participants enrolled: 90
- From 15 Apr 2026 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Low quality CT, non-homogeneous contrast agent perfusion
- Post-ablation CT performed in another center
- Patients in which pre- and post-ablation CTs do not share common phases
- Patients who underwent ethanol infusion in the vein of Marshall
Who the study is looking for
- Age≥18 years at the time of AF ablation
- AF ablation by pulse-field ablation (BOSTON SCIENTIFIC FARAPULSE) or by radiofrequency (any manufacturer) between 2020 and 2024
- Paroxysmal or non-paroxysmal AF
- Pre-ablation CT data available and of high quality
- Post-ablation CT data available and of high quality
- Post-ablation CT performed 3-months (+- 2 weeks) after AF ablation
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Pitie-Salpetriere Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.